Latest RuiYi Inc. Stories
Experienced Financial and Operational Leader to Support Global Development of Novel Monoclonal Antibody Therapeutics to GPCRs LA JOLLA, Calif. and SHANGHAI, Sept.
LA JOLLA, Calif.
New antibodies generated with RuiYi's iCAPS technology to explore GPCR structure and function LA JOLLA, Calif.
Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi's iCAPS platform LA JOLLA, Calif. and SHANGHAI, March 27, 2014 /PRNewswire/ -- RuiYi, Inc.
- An armed gangster.